PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Parabilis Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$25.35+2.60 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $732.82M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
6 of Parabilis Medicines's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Sep 15, 2026 | Sep 15, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 28, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 22, 2026 | Aug 25, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 13, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 13, 2026 | Aug 13, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 9, 2026 | Jun 11, 2026 | SEC EDGAR |